This report provides a 360-degree strategic analysis of the Global Pharmacogenomics, Theranostics, and Companion Diagnostics (CDx) Market, forecasting its trajectory from 2026 to 2036.
Global Pharmacogenomics, Theranostics, and Companion Diagnostics (CDx) Market Report (2026–2036)
1. Market Executive Summary
The convergence of pharmacogenomics, theranostics, and companion diagnostics represents the cornerstone of Personalized Medicine. This market is driven by the paradigm shift from "one-size-fits-all" blockbuster drugs to targeted therapies that ensure the right patient receives the right drug at the right dose. By integrating diagnostic testing with therapeutic intervention, this sector significantly reduces adverse drug reactions (ADRs) and improves clinical outcomes.
-
Market Valuation (2025 Est.): USD 8.4 Billion
-
Projected Valuation (2036): USD 19.8 Billion
-
CAGR (2026–2036): 8.1%
2. Competitive Landscape: Key Players
The market is characterized by strategic collaborations between pharmaceutical giants and specialized diagnostic developers.
Leading Diagnostic & Tech Providers:
-
F. Hoffmann-La Roche Ltd. (Leader in IHC and Oncology CDx)
-
Qiagen N.V. (Specialist in PCR and NGS-based diagnostics)
-
Agilent Technologies, Inc. (Leading provider of Dako-branded pathology solutions)
-
Thermo Fisher Scientific Inc. (Dominant in NGS and PCR platforms)
-
Illumina, Inc. (The backbone of genomic sequencing technology)
-
Abbott Laboratories (Focus on molecular and point-of-care diagnostics)
-
bioMérieux SA (Leader in microbiology and infectious disease diagnostics)
-
Myriad Genetics, Inc. (Pioneer in hereditary cancer and pharmacogenomics)
-
Danaher Corporation (Leica Biosystems) (Specialist in anatomical pathology)
Strategic Pharmaceutical Players:
-
Novartis AG
-
Pfizer Inc.
-
AstraZeneca
-
Bristol Myers Squibb (BMS)
-
Merck & Co. (MSD)
3. Comprehensive Market Segmentation
By Technology
-
Next-Generation Sequencing (NGS): Fastest-growing segment due to the ability to screen multiple biomarkers simultaneously.
-
Polymerase Chain Reaction (PCR): The gold standard for rapid, targeted genetic testing.
-
Immunohistochemistry (IHC): Essential for protein expression analysis in solid tumors.
-
In-situ Hybridization (ISH): Primarily used for gene amplification and translocation detection (e.g., HER2, ALK).
-
Microarrays: High-throughput screening for pharmacogenomic variations.
By Application/Indication
-
Oncology: Dominates over 60% of the market share, driven by immunotherapy and kinase inhibitors.
-
Neurological Disorders: Growing demand for testing in psychiatry (antidepressants) and Alzheimer’s.
-
Cardiovascular Disease (CVD): Focus on antiplatelet and anticoagulant dosing (e.g., CYP2C19 testing).
-
Infectious Diseases: Rapid growth in managing HIV and Hepatitis C therapy.
-
Immunological Disorders: Targeted biologics for RA and Crohn’s disease.
By Product & Service
-
Assays, Kits & Reagents: Recurring revenue stream for diagnostic manufacturers.
-
Instruments & Platforms: Capital equipment including sequencers and slide scanners.
-
Laboratory Services: Outsourced testing for hospitals and clinical trial support.
4. Regional Analysis
-
North America (United States & Canada): Holds the largest market share (approx. 44%). Driven by the FDA’s mandatory labeling for pharmacogenomic info and high investment in oncology research.
-
Europe: Strong focus on the EU IVDR (In Vitro Diagnostic Regulation) compliance and standardized healthcare reimbursement models in Germany, France, and the UK.
-
Asia-Pacific (China, Japan, India): Fastest-growing region. Driven by large patient pools, the rise of domestic biotech firms in China, and proactive government genomic initiatives in India and Singapore.
-
LAMEA: Emerging markets in Brazil and UAE are witnessing increased adoption of personalized medicine in private healthcare sectors.
5. Porter’s Five Forces Analysis
-
Bargaining Power of Suppliers (Moderate): Specialist enzymes and chemical reagents are controlled by a few giants like Thermo Fisher and Merck Millipore.
-
Bargaining Power of Buyers (High): Large hospital networks and health insurers demand significant discounts on diagnostic kits and demand clinical utility data.
-
Threat of New Entrants (Low to Moderate): Extremely high barriers due to stringent regulatory approvals (FDA Premarket Approval) and patent-protected technologies.
-
Threat of Substitutes (Low): No viable alternative to genetic/molecular testing for targeted therapy selection currently exists.
-
Competitive Rivalry (High): Intense competition between diagnostic firms to secure "Co-Development" agreements with Big Pharma.
6. SWOT Analysis
-
Strengths: High clinical efficacy; reduction in healthcare costs by avoiding ineffective treatments; strong intellectual property.
-
Weaknesses: High cost of NGS-based tests; limited reimbursement for multi-gene panels in developing nations.
-
Opportunities: Expansion into Liquid Biopsy (non-invasive CDx); integration of AI for genomic data interpretation.
-
Threats: Complex regulatory landscapes; concerns over genetic data privacy and ethical use.
7. Strategic Trend Analysis
-
Liquid Biopsy CDx: Moving away from tissue biopsies toward blood-based testing for real-time therapy monitoring.
-
Decentralized Testing: Shift from central labs to local hospitals through automated, easy-to-use molecular platforms.
-
The "Pan-Cancer" Approach: Developing diagnostics that target specific mutations (like NTRK) regardless of the tumor’s location.
-
AI-Driven Diagnostics: Using machine learning to identify novel biomarkers and predict patient drug responses from vast datasets.
8. Drivers & Challenges
-
Driver: The global increase in cancer incidence and the surge in FDA-approved targeted biologics.
-
Driver: Growing patient awareness and demand for personalized care to minimize toxic side effects.
-
Challenge: Lack of standardized guidelines for interpreting pharmacogenomic data across different labs.
-
Challenge: High capital expenditure required for setting up sophisticated genomic facilities.
9. Value Chain Analysis
-
R&D: Discovery of genetic biomarkers and validation of drug-diagnostic pairs.
-
Manufacturing: Production of sterile, high-precision assay kits and instrumentation.
-
Regulatory Approval: Simultaneous filing for drug (NDA) and diagnostic (PMA).
-
Clinical Implementation: Healthcare providers ordering tests and genetic counselors interpreting results.
-
Reimbursement: Insurance coverage based on clinical outcome improvements.
10. Quick Recommendations for Stakeholders
-
For Diagnostic Manufacturers: Focus on Multiplexing capabilities. Clinics prefer a single test that screens for multiple actionable mutations rather than several individual tests.
-
For Pharmaceutical Companies: Engage with CDx partners at Phase I of drug development. Early integration reduces clinical trial costs and increases the success rate of drug approvals.
-
For Investors: Target companies specializing in Bioinformatics and Cloud-based genomic analysis, as data interpretation is currently the primary bottleneck in the industry.
-
For Healthcare Providers: Invest in Genetic Counseling services to translate complex molecular data into actionable clinical decisions for patients.
Table of Contents
Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) global market
1 Industry Overview of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)
1.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Overview
1.1.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Scope
1.1.2 Market Status and Outlook
1.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Analysis by Regions ()
1.2.1 United States
1.2.2 Europe
1.2.3 China
1.2.4 Japan
1.2.5 Southeast Asia
1.2.6 India
1.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market by Type
1.3.1 PCR
1.3.2 In-situ Hybridization
1.3.3 Immunohistochemistry
1.3.4 Sequencing
1.3.5 Others
1.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market by End Users/Application
1.4.1 Oncology
1.4.2 Neurological Disorders
1.4.3 Cardiovascular Disease
1.4.4 Immunological Disorders
1.4.5 Others
2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Competition Analysis by Players
2.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Value) by Players ()
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future
3 Company (Top Players) Profiles
3.1 Qiagen NV
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) ()
3.2 GE Healthcare
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) ()
3.3 Agilent Technologies
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) ()
3.4 F Hoffman La Roche
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) ()
3.5 Foundation Medicine
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) ()
3.6 Thermo Fisher Scientific Inc.
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) ()
3.7 Leica Biosystems Nussloch GmBH
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) ()
3.8 Pfizer
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) ()
4 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type and Application ()
4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type ()
4.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
4.3 Potential Application of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) in Future
4.4 Top Consumer/End Users of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)
5 United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Development Status and Outlook
5.1 United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size ()
5.2 United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Market Share by Players ()
5.3 United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
6 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Development Status and Outlook
6.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size ()
6.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Market Share by Players ()
6.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
7 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Development Status and Outlook
7.1 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size ()
7.2 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Market Share by Players ()
7.3 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
8 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Development Status and Outlook
8.1 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size ()
8.2 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Market Share by Players ()
8.3 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
9 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Development Status and Outlook
9.1 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size ()
9.2 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Market Share by Players ()
9.3 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
10 India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Development Status and Outlook
10.1 India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size ()
10.2 India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Market Share by Players ()
10.3 India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
11 Market Forecast by Regions, Type and Application ()
11.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Value) by Regions ()
11.1.1 United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate ()
11.1.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate ()
11.1.3 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate ()
11.1.4 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate ()
11.1.5 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate ()
11.1.6 India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate ()
11.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Value) by Type ()
11.3 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
12 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Dynamics
12.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Opportunities
12.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Challenge and Risk
12.2.1 Competition from Opponents
12.2.2 Downside Risks of Economy
12.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Constraints and Threat
12.3.1 Threat from Substitute
12.3.2 Government Policy
12.3.3 Technology Risks
12.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Driving Force
12.4.1 Growing Demand from Emerging Markets
12.4.2 Potential Application
13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs Trend/Customer Preference
13.3 External Environmental Change
13.3.1 Economic Fluctuations
13.3.2 Other Risk Factors
14 Research Finding/Conclusion
15 Appendix
Methodology
Analyst Introduction
Data Source
List of Tables and Figures
Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) Status and Outlook ()
Table Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) Comparison by Regions ()
Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share by Regions ()
Figure United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate by Regions ()
Figure Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate by Regions ()
Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate by Regions ()
Figure Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate by Regions ()
Figure Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate by Regions ()
Figure India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate by Regions ()
Table Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (%) Comparison by Product ()
Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Type in 2017
Figure PCR Market Size (Million USD) and Growth Rate ()
Figure In-situ Hybridization Market Size (Million USD) and Growth Rate ()
Figure Immunohistochemistry Market Size (Million USD) and Growth Rate ()
Figure Sequencing Market Size (Million USD) and Growth Rate ()
Figure Others Market Size (Million USD) and Growth Rate ()
Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share by Application in 2017
Figure Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate in Oncology ()
Figure Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate in Neurological Disorders ()
Figure Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate in Cardiovascular Disease ()
Figure Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate in Immunological Disorders ()
Figure Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate in Others ()
Table Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) by Players ()
Figure Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2013
Figure Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2017
Table Qiagen NV Basic Information List
Table Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue (Million USD) of Qiagen NV ()
Figure Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue Market Share ()
Table GE Healthcare Basic Information List
Table Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue (Million USD) of GE Healthcare ()
Figure GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue Market Share ()
Table Agilent Technologies Basic Information List
Table Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue (Million USD) of Agilent Technologies ()
Figure Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue Market Share ()
Table F Hoffman La Roche Basic Information List
Table Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue (Million USD) of F Hoffman La Roche ()
Figure F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue Market Share ()
Table Foundation Medicine Basic Information List
Table Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue (Million USD) of Foundation Medicine ()
Figure Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue Market Share ()
Table Thermo Fisher Scientific Inc. Basic Information List
Table Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue (Million USD) of Thermo Fisher Scientific Inc. ()
Figure Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue Market Share ()
Table Leica Biosystems Nussloch GmBH Basic Information List
Table Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue (Million USD) of Leica Biosystems Nussloch GmBH ()
Figure Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue Market Share ()
Table Pfizer Basic Information List
Table Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue (Million USD) of Pfizer ()
Figure Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business Revenue Market Share ()
Table Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) by Product ()
Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share (%) by Product ()
Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share by Product in 2017
Table Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share (%) by Application in 2017
Table Top Consumer/End Users of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)
Figure United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate ()
Table United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) by Players ()
Figure United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2013
Figure United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2017
Table United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
Figure United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share (%) by Application ()
Figure United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Application in 2017
Figure Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate ()
Table Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) by Players ()
Figure Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2013
Figure Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2017
Table Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
Figure Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share (%) by Application ()
Figure Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Application in 2017
Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate ()
Table China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) by Players ()
Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2013
Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2017
Table China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share (%) by Application ()
Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Application in 2017
Figure Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate ()
Table Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) by Players ()
Figure Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2013
Figure Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2017
Table Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
Figure Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share (%) by Application ()
Figure Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Application in 2017
Figure Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate ()
Table Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) by Players ()
Figure Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2013
Figure Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2017
Table Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
Figure Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share (%) by Application ()
Figure Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Application in 2017
Figure India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) and Growth Rate ()
Table India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) by Players ()
Figure India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2013
Figure India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Players in 2017
Table India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application ()
Figure India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share (%) by Application ()
Figure India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Application in 2017
Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate ()
Table Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) by Regions ()
Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share ()
Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Regions in 2025
Figure United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate ()
Figure Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate ()
Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate ()
Figure Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate ()
Figure Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate ()
Figure India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate ()
Table Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) by Type ()
Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Type in 2018
Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Share by Type in 2025
Table Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) by Application ()
Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (Million USD) by Application in 2018
Competitive Landscape: Key Players
The market is characterized by strategic collaborations between pharmaceutical giants and specialized diagnostic developers.
Leading Diagnostic & Tech Providers:
-
F. Hoffmann-La Roche Ltd. (Leader in IHC and Oncology CDx)
-
Qiagen N.V. (Specialist in PCR and NGS-based diagnostics)
-
Agilent Technologies, Inc. (Leading provider of Dako-branded pathology solutions)
-
Thermo Fisher Scientific Inc. (Dominant in NGS and PCR platforms)
-
Illumina, Inc. (The backbone of genomic sequencing technology)
-
Abbott Laboratories (Focus on molecular and point-of-care diagnostics)
-
bioMérieux SA (Leader in microbiology and infectious disease diagnostics)
-
Myriad Genetics, Inc. (Pioneer in hereditary cancer and pharmacogenomics)
-
Danaher Corporation (Leica Biosystems) (Specialist in anatomical pathology)
Strategic Pharmaceutical Players:
-
Novartis AG
-
Pfizer Inc.
-
AstraZeneca
-
Bristol Myers Squibb (BMS)
-
Merck & Co. (MSD)
3. Comprehensive Market Segmentation
By Technology
-
Next-Generation Sequencing (NGS): Fastest-growing segment due to the ability to screen multiple biomarkers simultaneously.
-
Polymerase Chain Reaction (PCR): The gold standard for rapid, targeted genetic testing.
-
Immunohistochemistry (IHC): Essential for protein expression analysis in solid tumors.
-
In-situ Hybridization (ISH): Primarily used for gene amplification and translocation detection (e.g., HER2, ALK).
-
Microarrays: High-throughput screening for pharmacogenomic variations.
By Application/Indication
-
Oncology: Dominates over 60% of the market share, driven by immunotherapy and kinase inhibitors.
-
Neurological Disorders: Growing demand for testing in psychiatry (antidepressants) and Alzheimer’s.
-
Cardiovascular Disease (CVD): Focus on antiplatelet and anticoagulant dosing (e.g., CYP2C19 testing).
-
Infectious Diseases: Rapid growth in managing HIV and Hepatitis C therapy.
-
Immunological Disorders: Targeted biologics for RA and Crohn’s disease.
By Product & Service
-
Assays, Kits & Reagents: Recurring revenue stream for diagnostic manufacturers.
-
Instruments & Platforms: Capital equipment including sequencers and slide scanners.
-
Laboratory Services: Outsourced testing for hospitals and clinical trial support.
